Chinese journal of cancer research = Chung-kuo yen cheng yen chiu最新文献

{"title":"Comments on <i>National guidelines for diagnosis and treatment of esophageal carcinoma 2022 in China (English version)</i>.","authors":"Yuan Feng,&nbsp;Nan Wu","doi":"10.21147/j.issn.1000-9604.2022.06.11","DOIUrl":"https://doi.org/10.21147/j.issn.1000-9604.2022.06.11","url":null,"abstract":"","PeriodicalId":9830,"journal":{"name":"Chinese journal of cancer research = Chung-kuo yen cheng yen chiu","volume":"34 6","pages":"633-634"},"PeriodicalIF":0.0,"publicationDate":"2022-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9829500/pdf/cjcr-34-6-633.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9151726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to Comments on <i>National guidelines for diagnosis and treatment of thyroid cancer 2022 in China (English version)</i>.","authors":"","doi":"10.21147/j.issn.1000-9604.2022.06.14","DOIUrl":"https://doi.org/10.21147/j.issn.1000-9604.2022.06.14","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.21147/j.issn.1000-9604.2022.05.02.].</p>","PeriodicalId":9830,"journal":{"name":"Chinese journal of cancer research = Chung-kuo yen cheng yen chiu","volume":"34 6","pages":"644"},"PeriodicalIF":0.0,"publicationDate":"2022-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9829498/pdf/cjcr-34-6-644.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10634463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic implications of tumor-infiltrating lymphocytes in association with programmed cell death ligand 1 expression in remnant gastric cancer.","authors":"Marina Alessandra Pereira,&nbsp;Marcus Fernando Kodama Pertille Ramos,&nbsp;André Roncon Dias,&nbsp;Leonardo Cardili,&nbsp;Rafael Dyer Rodrigues de Moraes,&nbsp;Renan Ribeiro E Ribeiro,&nbsp;Venancio Avancini Ferreira Alves,&nbsp;Bruno Zilberstein,&nbsp;Evandro Sobroza de Mello,&nbsp;Ulysses Ribeiro Jr","doi":"10.21147/j.issn.1000-9604.2022.06.09","DOIUrl":"https://doi.org/10.21147/j.issn.1000-9604.2022.06.09","url":null,"abstract":"<p><strong>Objective: </strong>Remnant gastric cancer (RGC) is usually associated with a worse prognosis. As they are less common and very heterogeneous tumors, new prognostic and reliable determinants are required to predict patients' clinical course for RGC. This study aimed to investigate the tumor-infiltrating lymphocytes (TILs) and programmed cell death ligand 1 (PD-L1) status as prognostic biomarkers in a cohort of patients with RGC to develop an immune-related score.</p><p><strong>Methods: </strong>Patients with gastric cancer (GC) who underwent curative intent gastrectomy were retrospectively investigated. RGC resections with histological diagnosis of gastric adenocarcinoma were enrolled in the study. The risk score based on immune parameters was developed using binary logistic regression analysis. RGCs were divided into high-risk (HR), intermediate-risk (IR), and low-risk (LR) groups based on their immune score. The markers (CD3+, CD4+/CD8+ T cells and PD-L1) were selected for their potential prognostic, therapeutic value, and evaluated by immunohistochemistry (IHC).</p><p><strong>Results: </strong>A total of 42 patients with RGC were enrolled in the study. The score based on immune parameters exhibited an accuracy of 79% [the area under the receiver operating characteristic curve (AUC)=0.79, 95% confidence interval (95% CI), 0.63-0.94, P=0.002], and the population was divided into 3 prognostic groups: 10 (23.8%) patients were classified as LR, 15 (35.7%) as IR, and 17 (40.5%) as HR groups. There were no differences in clinicopathological and surgical characteristics between the three groups. In survival analysis, HR and IR groups had worse disease-free survival and overall survival rates compared to the LR group. In the multivariate analysis, lymph node metastasis and the immune score risk groups were independent factors related to worse survival.</p><p><strong>Conclusions: </strong>A scoring system with immune-related markers was able to distinguish prognostic groups of RGC associated with survival. Accordingly, tumor-infiltrating immune lymphocytes and PD-L1 status may serve as a potential prognostic biomarker for patients with RGC.</p>","PeriodicalId":9830,"journal":{"name":"Chinese journal of cancer research = Chung-kuo yen cheng yen chiu","volume":"34 6","pages":"612-622"},"PeriodicalIF":0.0,"publicationDate":"2022-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9829495/pdf/cjcr-34-6-612.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9137329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in gastric cancer research will light the way to control this cancer.","authors":"Paulo Pimentel de Assumpção,&nbsp;Rommel Rodrigues Burbano","doi":"10.21147/j.issn.1000-9604.2022.06.04","DOIUrl":"https://doi.org/10.21147/j.issn.1000-9604.2022.06.04","url":null,"abstract":"<p><p>Gastric adenocarcinoma (GC) is one of the most heterogeneous cancers, posing challenges to wide applications of the discoveries when compared to other cancers. Nevertheless, the benefits of research in the fight against GC are extraordinary, and even taking in mind the immense complexity of this disease, optimism is a great message to take home. Recent advances in GC research will pave the way for GC effective control, helping to save lives, together with permitting sustainable real-life support for those needing complex and high-expense interventions.</p>","PeriodicalId":9830,"journal":{"name":"Chinese journal of cancer research = Chung-kuo yen cheng yen chiu","volume":"34 6","pages":"575-578"},"PeriodicalIF":0.0,"publicationDate":"2022-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9829496/pdf/cjcr-34-6-575.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9151725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comments on <i>National guidelines for diagnosis and treatment of melanoma 2022 in China (English version)</i>.","authors":"Jiaran Zhang,&nbsp;Lu Si,&nbsp;Jun Guo","doi":"10.21147/j.issn.1000-9604.2022.06.12","DOIUrl":"https://doi.org/10.21147/j.issn.1000-9604.2022.06.12","url":null,"abstract":"","PeriodicalId":9830,"journal":{"name":"Chinese journal of cancer research = Chung-kuo yen cheng yen chiu","volume":"34 6","pages":"635-636"},"PeriodicalIF":0.0,"publicationDate":"2022-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9829504/pdf/cjcr-34-6-635.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9151727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Heterogeneity of tumor-infiltrating myeloid cells in era of single-cell genomics.","authors":"Xiaojing Chu,&nbsp;Yu Zhang,&nbsp;Sijin Cheng","doi":"10.21147/j.issn.1000-9604.2022.06.01","DOIUrl":"https://doi.org/10.21147/j.issn.1000-9604.2022.06.01","url":null,"abstract":"<p><p>Tumor microenvironment (TME) is highly heterogeneous and composed of complex cellular components, including multiple kinds of immune cells. Among all immune cells in TME, tumor-infiltrating myeloid cells (TIMs) account for a large proportion and play roles as key regulators in a variety of functions, ranging from immune-mediated tumor killing to tumor immune evasion. Understanding the heterogeneity of TIMs will provide valuable insights for new therapeutic targeting of myeloid cells. Single-cell genomic technologies deciphering cell composition and gene expression at single-cell resolution have largely improved our understanding of the cellular heterogeneity of TIMs and highlighted several novel cell subtypes contributing to the variation of patient survival and treatment response. However, these cell subtypes were defined based on limited data without a concordant nomenclature, which makes it difficult to understand whether they exist in different studies. Thus, in this review, we comprehensively summarized the common agreements and current different opinions on the heterogeneity of TIMs gained from single-cell studies; evaluated the feasibility of current myeloid cell targets at single-cell level and proposed a uniform nomenclature for TIM subsets.</p>","PeriodicalId":9830,"journal":{"name":"Chinese journal of cancer research = Chung-kuo yen cheng yen chiu","volume":"34 6","pages":"543-553"},"PeriodicalIF":0.0,"publicationDate":"2022-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9829493/pdf/cjcr-34-6-543.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10640724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"National guidelines for diagnosis and treatment of malignant lymphoma 2022 in China (English version).","authors":"National Health Commission Of The People's Republic Of China","doi":"10.21147/j.issn.1000-9604.2022.05.01","DOIUrl":"https://doi.org/10.21147/j.issn.1000-9604.2022.05.01","url":null,"abstract":"","PeriodicalId":9830,"journal":{"name":"Chinese journal of cancer research = Chung-kuo yen cheng yen chiu","volume":" ","pages":"425-446"},"PeriodicalIF":0.0,"publicationDate":"2022-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9646456/pdf/cjcr-34-5-425.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40696174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comments on <i>National guidelines for diagnosis and treatment of cervical cancer 2022 in China (English version)</i>.","authors":"Naiyi Zhang,&nbsp;Yunong Gao","doi":"10.21147/j.issn.1000-9604.2022.05.06","DOIUrl":"https://doi.org/10.21147/j.issn.1000-9604.2022.05.06","url":null,"abstract":"","PeriodicalId":9830,"journal":{"name":"Chinese journal of cancer research = Chung-kuo yen cheng yen chiu","volume":" ","pages":"458-459"},"PeriodicalIF":0.0,"publicationDate":"2022-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9646452/pdf/cjcr-34-5-458.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40696179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comments on <i>National guidelines for diagnosis and treatment of thyroid cancer 2022 in China (English version)</i>.","authors":"Hao Wang,&nbsp;Jian Wang,&nbsp;Xiang Wang,&nbsp;Yiming Zhu,&nbsp;Yuqing Sun,&nbsp;Xin Zhang,&nbsp;Xiaorong Hou,&nbsp;Kun Zheng,&nbsp;Shaoyan Liu,&nbsp;Yansong Lin","doi":"10.21147/j.issn.1000-9604.2022.05.02","DOIUrl":"https://doi.org/10.21147/j.issn.1000-9604.2022.05.02","url":null,"abstract":"","PeriodicalId":9830,"journal":{"name":"Chinese journal of cancer research = Chung-kuo yen cheng yen chiu","volume":"34 5","pages":"447-450"},"PeriodicalIF":0.0,"publicationDate":"2022-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9646462/pdf/cjcr-34-5-447.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9187654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Myeloid checkpoints for cancer immunotherapy.","authors":"Yixin Qian,&nbsp;Ting Yang,&nbsp;Huan Liang,&nbsp;Mi Deng","doi":"10.21147/j.issn.1000-9604.2022.05.07","DOIUrl":"https://doi.org/10.21147/j.issn.1000-9604.2022.05.07","url":null,"abstract":"<p><p>Myeloid checkpoints are receptors on the myeloid cell surface which can mediate inhibitory signals to modulate anti-tumor immune activities. They can either inhibit cellular phagocytosis or suppress T cells and are thus involved in the pathogenesis of various diseases. In the tumor microenvironment, besides killing tumor cells by phagocytosis or activating anti-tumor immunity by tumor antigen presentation, myeloid cells could execute pro-tumor efficacies through myeloid checkpoints by interacting with counter-receptors on other immune cells or cancer cells. In summary, myeloid checkpoints may be promising therapeutic targets for cancer immunotherapy.</p>","PeriodicalId":9830,"journal":{"name":"Chinese journal of cancer research = Chung-kuo yen cheng yen chiu","volume":" ","pages":"460-482"},"PeriodicalIF":0.0,"publicationDate":"2022-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9646457/pdf/cjcr-34-5-460.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40695663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}